MARATTO

article · Ocular Immunology and Inflammation

Value of Serum Asymmetric Dimethylarginine (ADMA) As a Novel Biomarker for Uveitis in Behçet’s Disease

20243 citationsMinia University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Serum ADMA level can serve as a novel biomarker of uveitis in BD and its severity with good diagnostic accuracy, regardless of its site or activity.

Research topics

  • Ocular Diseases and Behçet’s Syndrome
  • Cerebral Venous Sinus Thrombosis
  • Retinal and Optic Conditions

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher siteRecord on OpenAlex

DOI: 10.1080/09273948.2024.2342378

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

Sign in to join the discussion

New to MARATTO™? Create a free account.